ストックスクリーナーアプリを入手
4.08
5.15%
0.20
前日終値:
$3.88
開ける：
$4.02
24時間の取引高:
28,090
Relative Volume:
0.11
時価総額：
$97.12M
収益：
-
当期純損益:
$-44.10M
株価収益率:
-1.9091
EPS:
-2.1371
ネットキャッシュフロー:
$-49.09M
1週間 パフォーマンス:
+0.25%
1か月 パフォーマンス:
-10.33%
6か月 パフォーマンス:
-52.83%
1年 パフォーマンス:
+79.74%
1日の値動き範囲:
$3.88
$4.15
1週間の範囲:
$3.84
$4.18
52週間の値動き範囲:
$2.31
$11.88
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
名前
Kalaris Therapeutics Inc
セクター
電話
650-249-2727
住所
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
4.08 | 93.79M | 0 | -44.10M | -49.09M | -2.1371 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-16 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-23 | 開始されました | Chardan Capital Markets | Buy |
| 2025-11-03 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-07-23 | 再開されました | Piper Sandler | Neutral |
| 2025-05-07 | 開始されました | Leerink Partners | Outperform |
| 2025-04-08 | 開始されました | William Blair | Outperform |
すべてを表示
Kalaris Therapeutics Inc (KLRS) 最新ニュース
Kalaris Therapeutics Reports Q2 Financial Results, Advances Clinical Program - VisionMonday.com
Kalaris Therapeutics, Inc. 2Q 2026: Net loss $(11.5M), Diluted EPS $(0.48) — 10-Q Summary - TradingView
Kalaris Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Kalaris Therapeutics Q2 Results: EPS beats estimate, losses narrow 21% YoY - scanx.trade
Kalaris Therapeutics, Inc. (NASDAQ: KLRS) Share Price, KLRS Stock News, KLRS Share Price & Updates - kalkine.ca
Form 8K Kalaris Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
Kalaris Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results - MarketBeat
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Kalaris Therapeutics Reports Q2 2026 Results and Advances Phase 1b/2 TH103 Study for Neovascular AMD - Quiver Quantitative
Kalaris Reports Q2 2026: $11.5M Quarterly Net Loss; $93.5M Cash on Hand - TradingView
KLRS: TH103 clinical progress and strong cash position support operations into Q4 2027 - TradingView
Kalaris Reports $11.5 Million Q2 Net Loss and TH103 Updates - Quiver Quantitative
BRIEF-Kalaris Therapeutics Inc Q2 Operating Income USD -12.386 Million Vs. IBES Estimate USD -12.5 Million - TradingView
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4%Here's What Happened - MarketBeat
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf - GlobeNewswire
Investigation launched into Kalaris Therapeutics board for possible fiduciary breaches since 2024 - pluang.com
Kalaris Therapeutics (KLRS) Holds Gains Near $3.51 as Stock Consolidates Between Key LevelsValue Stock Ideas - dars.gov.et
Kalaris Therapeutics (KLRS) Sees Modest Gain as Stock Holds Above SupportMA Cross Alert - dars.gov.et
Kalaris Therapeutics Inc (KLRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kalaris Therapeutics Inc (KLRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kalaris Therapeutics Inc (KLRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kalaris Therapeutics Inc (KLRS) Cash Flow - TradingKey
Kalaris Therapeutics Inc (KLRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
KLRS|Kalaris Therapeutics Inc|Price:3.730|Chg%:-0.190 - TradingKey
KLRS|Kalaris Therapeutics Inc|Price:3.830|Chg%:-0.110 - tradingkey.com
Kalaris Therapeutics Inc (KLRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kalaris Therapeutics (KLRS) Drops 3.7% as Stock Tests Key Support ZoneEarnings Quality Factor - dars.gov.et
Kalaris appoints Liisa Bayko as CFO - MSN
Why is Kalaris Therapeutics stock gaining Friday? - MSN
Kalaris Therapeutics Appoints Liisa Bayko as New Chief Financial Officer - VisionMonday.com
Kalaris Therapeutics files Form 3 for CFO Liisa Ann Bayko - Bitget
Kalaris Therapeutics appoints Liisa Bayko as CFO By Investing.com - Investing.com Nigeria
Kalaris Therapeutics appoints Liisa Bayko as CFO - Investing.com
Kalaris Therapeutics stock falls despite naming new CFO By Investing.com - Investing.com South Africa
Kalaris Therapeutics Appoints Liisa Bayko as New CFO - Contract Pharma
Kalaris Therapeutics stock falls despite naming new CFO - Investing.com
Kalaris Therapeutics, Inc. Announces Appointment of Liisa Bayko to Chief Financial Officer, Effective July 20, 2026 - marketscreener.com
Kalaris Therapeutics Strengthens Financial Leadership With New CFO - TipRanks
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer - The Manila Times
After more than two decades in biotech finance, Liisa Bayko joins Kalaris - Stock Titan
Kalaris Therapeutics appoints Liisa Bayko as Chief Financial Officer - scanx.trade
Kalaris Therapeutics Slides Nearly 5% as Support Levels Come into FocusFear Greed Extreme - dars.gov.et
Enterprise value to revenue forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView
KLRS Dips After Intraday Spike Draws Trader Interest - timothysykes.com
Kalaris Therapeutics Shares Rise After More Positive Data From TH103 Trial - Moomoo
KLRS Stock Dips As Traders React To Volatile Intraday Spike - StocksToTrade
Kalaris Therapeutics Inc (KLRS) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):